Barton Ford Haynes, MD

Professor of Medicine
Frederic M. Hanes Professor of Medicine
Director of the Human Vaccine Institute in the Department of Medicine
Research Professor of Global Health
Professor of Immunology
Member of the Duke Cancer Institute
Member of the Duke Human Vaccine Institute
Campus mail 106 Research Drive, MSRBII 4090, Durham, NC 27710
Phone (919) 684-5384
Email address hayne002@mc.duke.edu

The Haynes lab is studying host innate and adaptive immune responses to the human immunodeficiency virus (HIV), tuberculosis (TB), and influenza in order to find the enabling technology to make preventive vaccines against these three major infectious diseases.

Mucosal Immune Responses in Acute HIV Infection

The Haynes lab is working to determine why broadly neutralizing antibodies are rarely made in acute HIV infection (AHI), currently a major obstacle in the development of an HIV vaccine. The lab has developed a novel approach to define the B cell repertories in AHI in order to find neutralizing antibodies against the virus. This approach uses linear Immunoglobulin (Ig) heavy and light chain gene expression cassettes to express Ig V(H) and V(L) genes isolated from sorted single B cells as IgG1 antibody without a cloning step. This strategy was used to characterize the Ig repertoire of plasma cells/plasmablasts in AHI and to produce recombinant influenza mAbs from sorted single human plasmablasts after influenza vaccination.

The lab is also studying the earliest effect HIV-1 has on B cells. Analyzing blood and gut-associated lymphoid tissues (GALT) during acute HIV infection, they have found that as early as 17 days after transmission HIV-1 induces B cell class switching and 47 days after transmission, HIV-1 causes considerable damage to GALT germinal centers. They found that in AHI, GALT memory B cells induce polyclonal B cell activation due to the presence of HIV-1-specific, influenza-specific, and autoreactive antibodies. The team concluded from this study that early induction of polyclonal B cell differentiation, along with follicular damage and germinal center loss, may explain why HIV-1 induced antibody responses decline rapidly during acute HIV infection and why plasma antibody responses are delayed.

The lab is also looking at ways of generating long-lived memory B cell responses to HIV infection, another major hurdle in the development of a successful HIV-1 vaccine. The lab has found that in HIV-1 gp120 envelope vaccination and chronic HIV-1 infection, HIV-1 envelope induces predominantly short-lived memory B cell-dependent plasma antibodies.

Immunogen Design

To overcome the high level of genetic diversity in HIV-1 envelope genes, the Haynes lab is developing strategies to induce antibodies that cross-react with multiple strains of HIV. The lab has designed immunogens based on transmitted founder Envs and mosaic consensus Envs in collaboration with Dr. Bette Korber at Los Alamos National Laboratory. These immunogens are designed to induce antibodies that cross-react with a multiple subtype Env glycoproteins. The goal is to determine if cross-reactive mAbs to highly conserved epitopes in HIV-1 envelope glycoproteins can be induced. The team recently characterized a panel of ten mAbs that reacted with varying breadth to subtypes A, B, C, D, F, G, CRF01_AE, and a highly divergent SIVcpzUS Env protein. Two of the mAbs cross-reacted with all tested Env proteins, including SIVcpzUS Env and bound Env proteins with high affinity.

Mucosal Immune Responses in TB and Influenza

The Haynes lab is helping to develop novel approaches to TB vaccine development. The current therapeutic vaccine for TB, called BCG, may prevent complications from TB in children, but offers little protection against infection and disease in adults. The lab is focused on using live attenuated Mycobacterium tuberculosis mutants as vaccine candidates and is currently evaluating this approach in non-human primate studies. As part of the DHVI Influenza program, they are studying the B cell response to influenza in order to generate a “universal” flu vaccine. They are currently trying to express more highly conserved influenza antigens in recombinant vesicular stomatitis virus (rVSV) vectors in order to elicit robust T cell and antibody responses to those antigens.

Education and Training

  • M.D., Baylor University, 1973

Publications

Francke, U., B. E. Foellmer, and B. F. Haynes. “Chromosome mapping of human cell surface molecules: monoclonal anti-human lymphocyte antibodies 4F2, A3D8, and A1G3 define antigens controlled by different regions of chromosome 11..” Somatic Cell Genet 9, no. 3 (May 1983): 333–44.

PMID
6190235
Scholars@Duke

Reitz, M. S., M. Popovic, B. F. Haynes, S. C. Clark, and R. C. Gallo. “Relatedness by nucleic acid hybridization of new isolates of human T-cell leukemia-lymphoma virus (HTLV) and demonstration of provirus in uncultured leukemic blood cells..” Virology 126, no. 2 (April 30, 1983): 688–672.

PMID
6602415
Scholars@Duke

Haynes, B. F., S. E. Miller, T. J. Palker, J. O. Moore, P. H. Dunn, D. P. Bolognesi, and R. S. Metzgar. “Identification of human T cell leukemia virus in a Japanese patient with adult T cell leukemia and cutaneous lymphomatous vasculitis..” Proc Natl Acad Sci U S A 80, no. 7 (April 1983): 2054–58. https://doi.org/10.1073/pnas.80.7.2054.

PMID
6601276
Full Text

Haynes, B. F., M. Robert-Guroff, R. S. Metzgar, G. Franchini, V. S. Kalyanaraman, T. J. Palker, and R. C. Gallo. “Monoclonal antibody against human T cell leukemia virus p19 defines a human thymic epithelial antigen acquired during ontogeny..” J Exp Med 157, no. 3 (March 1, 1983): 907–20. https://doi.org/10.1084/jem.157.3.907.

PMID
6833950
Full Text

Haynes, B. F., R. W. Warren, R. H. Buckley, J. E. McClure, A. L. Goldstein, F. W. Henderson, L. L. Hensley, and G. S. Eisenbarth. “Demonstration of abnormalities in expression of thymic epithelial surface antigens in severe cellular immunodeficiency diseases..” J Immunol 130, no. 3 (March 1983): 1182–88.

PMID
6600476
Scholars@Duke

Fauci, A. S., B. F. Haynes, P. Katz, and S. M. Wolff. “Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years..” Ann Intern Med 98, no. 1 (January 1983): 76–85.

PMID
6336643
Scholars@Duke

Buckley, R. H., S. Gard, B. F. Haynes, L. J. Sindel, K. Davis, H. A. Sampson, M. E. Ruff, and H. S. Koren. “Severe combined immunodeficiency (SCID) with natural killer (NK) cell predominance..” Birth Defects Orig Artic Ser 19, no. 3 (1983): 101–4.

PMID
6360230
Scholars@Duke

Haynes, B. F., R. W. Warren, R. H. Buckley, J. E. McClure, A. L. Goldstein, F. W. Henderson, L. L. Hensley, and G. S. Eisenbarth. “Demonstration of abnormalities in expression of thymic epithelial surface antigens in severe cellular immunodeficiency diseases..” Birth Defects Orig Artic Ser 19, no. 3 (1983): 255–58.

PMID
6606445
Scholars@Duke

Matutes, E., D. Robinson, M. O’Brien, B. F. Haynes, H. Zola, and D. Catovsky. “Candidate counterparts of Sézary cells and adult T-cell lymphoma-leukaemia cells in normal peripheral blood: an ultrastructural study with the immunogold method and monoclonal antibodies..” Leuk Res 7, no. 6 (1983): 787–801.

PMID
6607389
Scholars@Duke

Steinberg, A. D., A. Fauci, and B. F. Haynes. “Assessing treatments with cyclophosphamide.” Annals of Internal Medicine 98, no. 6 (1983): 1026–27.

Scholars@Duke

Pages